Metabolomics at the tumor microenvironment interface: Decoding cellular conversations.
cancer metabolism
glucose
immunotherapy
metabolic interventions
spatial biology
Journal
Medicinal research reviews
ISSN: 1098-1128
Titre abrégé: Med Res Rev
Pays: United States
ID NLM: 8103150
Informations de publication
Date de publication:
26 Dec 2023
26 Dec 2023
Historique:
revised:
08
11
2023
received:
21
09
2023
accepted:
07
12
2023
medline:
26
12
2023
pubmed:
26
12
2023
entrez:
26
12
2023
Statut:
aheadofprint
Résumé
Cancer heterogeneity remains a significant challenge for effective cancer treatments. Altered energetics is one of the hallmarks of cancer and influences tumor growth and drug resistance. Studies have shown that heterogeneity exists within the metabolic profile of tumors, and personalized-combination therapy with relevant metabolic interventions could improve patient response. Metabolomic studies are identifying novel biomarkers and therapeutic targets that have improved treatment response. The spatial location of elements in the tumor microenvironment are becoming increasingly important for understanding disease progression. The evolution of spatial metabolomics analysis now allows scientists to deeply understand how metabolite distribution contributes to cancer biology. Recently, these techniques have spatially resolved metabolite distribution to a subcellular level. It has been proposed that metabolite mapping could improve patient outcomes by improving precision medicine, enabling earlier diagnosis and intraoperatively identifying tumor margins. This review will discuss how altered metabolic pathways contribute to cancer progression and drug resistance and will explore the current capabilities of spatial metabolomics technologies and how these could be integrated into clinical practice to improve patient outcomes.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cancer Australia
Informations de copyright
© 2023 The Authors. Medicinal Research Reviews published by Wiley Periodicals LLC.
Références
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81-94.
Sun C, Li T, Song X, et al. Spatially resolved metabolomics to discover tumor-associated metabolic alterations. Proc Natl Acad Sci USA. 2019;116:52-57.
Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27-47.
Icard P, Shulman S, Farhat D, Steyaert JM, Alifano M, Lincet H. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updates. 2018;38:1-11.
Baghban R, Roshangar L, Jahanban-Esfahlan R, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signaling. 2020;18:59.
de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374-403.
Zhang Y, Zhai Z, Duan J, et al. Lactate: the mediator of metabolism and immunosuppression. Front Endocrinol. 2022;13:901495.
Lieu EL, Nguyen T, Rhyne S, Kim J. Amino acids in cancer. Exp Mol Med. 2020;52:15-30.
Ganesh S, Hu T, Woods E, et al. Spatially resolved 3D metabolomic profiling in tissues. Sci Adv. 2021;7:eabd0957.
Zhang W, Li S, Li C, Li T, Huang Y. Remodeling tumor microenvironment with natural products to overcome drug resistance. Front Immunol. 2022;13:1051998.
Hefzi H, Palsson BO, Lewis NE. Chapter 12-reconstruction of genome-scale metabolic networks. In: Walhout AJM, Vidal M, Dekker J, eds. Handbook of Systems Biology. Academic Press; 2013:229-250.
Park JH, Pyun WY, Park HW. Cancer metabolism: phenotype, signaling and therapeutic targets. Cells. 2020;9:2308.
Sainero-Alcolado L, Liaño-Pons J, Ruiz-Pérez MV, Arsenian-Henriksson M. Targeting mitochondrial metabolism for precision medicine in cancer. Cell Death Differ. 2022;29:1304-1317.
Damaghi M, West J, Robertson-Tessi M, et al. The harsh microenvironment in early breast cancer selects for a Warburg phenotype. Proc Natl Acad Sci USA. 2021;118:e2011342118.
Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27:441-464.
Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41:211-218.
Warburg O. The metabolism of carcinoma cells. J Cancer Res. 1925;9:148-163.
Warburg, O, Wind, F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519-530.
Vaupel P, Multhoff G. Revisiting the Warburg effect: historical dogma versus current understanding. J Physiol. 2021;599:1745-1757.
Zhang Z, Bao C, Jiang L, et al. When cancer drug resistance meets metabolomics (bulk, single-cell and/or spatial): progress, potential, and perspective. Front Oncol. 2023;12:1054233.
Siska PJ, Singer K, Evert K, Renner K, Kreutz M. The immunological Warburg effect: can a metabolic-tumor-stroma score (MeTS) guide cancer immunotherapy? Immunol Rev. 2020;295:187-202.
Zhao S, Peralta RM, Avina-Ochoa N, Delgoffe GM, Kaech SM. Metabolic regulation of T cells in the tumor microenvironment by nutrient availability and diet. Sem Immunol. 2021;52:101485.
Hume DA, Radik JL, Ferber E, Weidemann MJ. Aerobic glycolysis and lymphocyte transformation. Biochem J. 1978;174:703-709.
DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 2007;104:19345-19350.
Wang Z-H, Peng W-B, Zhang P, Yang X-P, Zhou Q. Lactate in the tumour microenvironment: from immune modulation to therapy. EBioMedicine. 2021;73:103627.
Jones W, Bianchi K. Aerobic glycolysis: beyond proliferation. Front Immunol. 2015;6:227.
Cheng S-C, Quintin J, Cramer RA, et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345:1250684.
Moindjie H, Rodrigues-Ferreira S, Nahmias C. Mitochondrial metabolism in carcinogenesis and cancer therapy. Cancers. 2021;13:3311.
Zu XL, Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun. 2004;313:459-465.
Nakashima RA, Paggi MG, Pedersen PL. Contributions of glycolysis and oxidative phosphorylation to adenosine 5′-triphosphate production in AS-30D hepatoma cells. Cancer Res. 1984;44:5702-5706.
Ziello JE, Jovin IS, Huang Y. Hypoxia-inducible factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med. 2007;80:51-60.
Siska PJ, Jiao J, Matos C, et al. Kynurenine induces T cell fat catabolism and has limited suppressive effects in vivo. EBioMedicine. 2021;74:103734.
Payen VL, Porporato PE, Baselet B, Sonveaux P. Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway. Cell Mol Life Sci. 2016;73:1333-1348.
Lee GH, et al. Lysyl oxidase-like-1 enhances lung metastasis when lactate accumulation and monocarboxylate transporter expression are involved. Oncol Lett. 2011;2:831-838.
Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem. 2006;281:9030-9037.
Petersen C, Nielsen MD, Andersen ES, et al. MCT1 and MCT4 expression and lactate flux activity increase during white and brown adipogenesis and impact adipocyte metabolism. Sci Rep. 2017;7:13101.
Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109:3812-3819.
Stone SC, Rossetti RAM, Alvarez KLF, et al. Lactate secreted by cervical cancer cells modulates macrophage phenotype. J Leukoc Biol. 2019;105:1041-1054.
Vlachostergios PJ, Oikonomou KG, Gibilaro E, Apergis G. Elevated lactic acid is a negative prognostic factor in metastatic lung cancer. Cancer Biomarkers. 2015;15:725-734.
Shih CC, Lee TS, Tsuang FY, et al. Pretreatment serum lactate level as a prognostic biomarker in patients undergoing supratentorial primary brain tumor resection. Oncotarget. 2017;8:63715-63723.
Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015;25:771-784.
Patra S, Elahi N, Armorer A, et al. Mechanisms governing metabolic heterogeneity in breast cancer and other tumors. Front Oncol. 2021;11:700629.
Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4-22.
Du A, Wang Z, Huang T, et al. Fatty acids in cancer: metabolic functions and potential treatment. MedComm Oncol. 2023;2:e25.
Halimi H, Farjadian S. Cholesterol: an important actor on the cancer immune scene. Front Immunol. 2022;13:2692.
Resh MD. Fatty acylation of proteins: the long and the short of it. Prog Lipid Res. 2016;63:120-131.
Chen Y, Hughes-Fulford M. Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2. Int J Cancer. 2001;91:41-45.
Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012;367:1792-1802.
Chang W-T, Lin H-W, Lin S-H, Li Y-H. Association of statin use with cancer- and noncancer-associated survival among patients with breast cancer in Asia. JAMA Netw Open. 2023;6:e239515.
Beckwitt CH, Clark AM, Ma B, Whaley D, Oltvai ZN, Wells A. Statins attenuate outgrowth of breast cancer metastases. Br J Cancer. 2018;119:1094-1105.
Jin L, Alesi GN, Kang S. Glutaminolysis as a target for cancer therapy. Oncogene. 2016;35:3619-3625.
Cruzat V, Macedo Rogero M, Noel Keane K, Curi R, Newsholme P. Glutamine: metabolism and immune function, supplementation and clinical translation. Nutrients. 2018;10:1564.
Yang L, Venneti S, Nagrath D. Glutaminolysis: a hallmark of cancer metabolism. Annu Rev Biomed Eng. 2017;19:163-194.
Qiu F, Chen YR, Liu X, et al. Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. Sci Signaling. 2014;7:ra31.
Krall AS, Xu S, Graeber TG, Braas D, Christofk HR. Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nat Commun. 2016;7:11457.
Lo M, Ling V, Wang YZ, Gout PW. The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer. 2008;99:464-472.
Chen C, Wang Z, Qin Y. Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy. Front Pharmacol. 2022;13:935536.
Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell. 2013;153:38-55.
Icard P, Kafara P, Steyaert J-M, Schwartz L, Lincet H. The metabolic cooperation between cells in solid cancer tumors. Biochim Biophys Acta Rev Cancer. 2014;1846:216-225.
Li J, Harris RA, Cheung SW, et al. Genomic hypomethylation in the human germline associates with selective structural mutability in the human genome. PLoS Genet. 2012;8:e1002692.
Kumar A, Chamoto K, Chowdhury PS, Honjo T. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy. eLife. 2020;9:e52330.
Leone RD, Powell JD. Fueling the revolution: targeting metabolism to enhance immunotherapy. Cancer Immunol Res. 2021;9:255-260.
Peng X, Chen Z, Farshidfar F, et al. Molecular characterization and clinical relevance of metabolic expression subtypes in human cancers. Cell Rep. 2018;23:255-269.
Gaude E, Frezza C. Tissue-specific and convergent metabolic transformation of cancer correlates with metastatic potential and patient survival. Nat Commun. 2016;7:13041.
Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discovery. 2022;21:141-162.
Schmidt DR, Patel R, Kirsch DG, Lewis CA, Vander Heiden MG, Locasale JW. Metabolomics in cancer research and emerging applications in clinical oncology. CA Cancer J Clin. 2021;71:333-358.
Tammemägi MC, Berg CD, Riley TL, Cunningham CR, Taylor KL. Impact of lung cancer screening results on smoking cessation. J Natl Cancer Inst. 2014;106:dju084.
Mendes C, Serpa J. Metabolic remodelling: an accomplice for new therapeutic strategies to fight lung cancer. Antioxidants. 2019;8:603.
Fan TW, Lane AN, Higashi RM, et al. Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM). Mol Cancer. 2009;8:41.
Li X, Liu M, Liu H, Chen J. Tumor metabolic reprogramming in lung cancer progression. Oncol Lett. 2022;24:287.
Romero OA, Torres-Diz M, Pros E, et al. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discovery. 2014;4:292-303.
Xu S, Herschman HR. A tumor agnostic therapeutic strategy for hexokinase 1-null/hexokinase 2-positive cancers. Cancer Res. 2019;79:5907-5914.
Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16:619-634.
Dunphy MPS, Harding JJ, Venneti S, et al. In vivo PET assay of tumor glutamine flux and metabolism: in-human trial of 18F-(2S,4R)-4-fluoroglutamine. Radiology. 2018;287:667-675.
Nunes SC, Ramos C, Lopes-Coelho F, et al. Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity. Sci Rep. 2018;8:9513.
Sun RC, Denko NC. Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab. 2014;19:285-292.
Gong Y, Ji P, Yang YS, et al. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab. 2021;33:51-64.
Xiao Y, Ma D, Yang YS, et al. Comprehensive metabolomics expands precision Medicine for triple-negative breast cancer. Cell Res. 2022;32:477-490.
Plana D, Palmer AC, Sorger PK. Independent drug action in combination therapy: implications for precision oncology. Cancer Discovery. 2022;12:606-624.
Zaal EA, Berkers CR. The influence of metabolism on drug response in cancer. Front Oncol. 2018;8:500.
Obrist F, Michels J, Durand S, et al. Metabolic vulnerability of cisplatin-resistant cancers. EMBO J. 2018;37:500.
Li W, Tanikawa T, Kryczek I, et al. Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer. Cell Metab. 2018;28:87-103.
Steendam CMJ, Ernst SM, Badrising SK, et al. Chemotherapy for patients with EGFR mutated NSCLC after progression on EGFR-TKI's: exploration of efficacy of unselected treatment in a multicenter cohort study. Lung Cancer. 2023;181:107248.
Li H, Stokes W, Chater E, et al. Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer. Cell Discov. 2016;2:16031.
Serizawa M, Kusuhara M, Zangiacomi V, et al. Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells. Anticancer Res. 2014;34:2779-2787.
Ma Q, Wang J, Ren Y, Meng F, Zeng L. Pathological mechanistic studies of osimertinib resistance in non-small-cell lung cancer cells using an integrative metabolomics-proteomics analysis. J Oncol. 2020;2020:6249829.
Du Z-X, Zhang H-Y, Meng X, Guan Y, Wang H-Q. Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells. BMC Cancer. 2009;9:56.
Cohen EEW, Bell RB, Bifulco CB, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019;7:184.
Wang D, Liu J, Wang C, et al. Microbial synthesis of Prussian blue for potentiating checkpoint blockade immunotherapy. Nat Commun. 2023;14:2943.
Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol: Mech Dis. 2021;16:223-249.
Li H, Xiao Y, Li Q, et al. The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell. 2022;40:36-52.
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10:727-742.
Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8:2171-2186.
Cao G, Xiao Z, Yin Z. Normalization cancer immunotherapy: blocking Siglec-15! Signal Transduct Target Ther. 2019;4:10.
Zhang J, Yan Y, Li J, Adhikari R, Fu L. PD-1/PD-L1 based combinational cancer therapy: icing on the cake. Front Pharmacol. 2020;11:722.
Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86.
Mei Z, Huang J, Qiao B, Lam AK. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Int J Oral Sci. 2020;12:16.
Chen Y, Li Z-Y, Zhou G-Q, Sun Y. An immune-related gene prognostic index for head and neck squamous cell carcinoma. Clin Cancer Res. 2021;27:330-341.
Makarem N, Bandera EV, Nicholson JM, Parekh N. Consumption of sugars, sugary foods, and sugary beverages in relation to cancer risk: a systematic review of longitudinal studies. Annu Rev Nutr. 2018;38:17-39.
Qian L, Zhang F, Yin M, Lei Q. Cancer metabolism and dietary interventions. Cancer Biol Med. 2021;19:163-174.
Kikomeko J, Schutte T, van Velzen MJM, Seefat R, van Laarhoven HWM. Short-term fasting and fasting mimicking diets combined with chemotherapy: a narrative review. Ther Adv Med Oncol. 2023;15:17588359231161418.
Raffaghello L, Lee C, Safdie FM, et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci USA. 2008;105:8215-8220.
Ligorio F, Fucà G, Provenzano L, et al. Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: a sub-analysis of the NCT03340935 trial. Eur J Cancer. 2022;172:300-310.
Liu X, Peng S, Tang G, et al. Fasting-mimicking diet synergizes with ferroptosis against quiescent, chemotherapy-resistant cells. EBioMedicine. 2023;90:104496.
Vernieri C, Casola S, Foiani M, Pietrantonio F, de Braud F, Longo V. Targeting cancer metabolism: dietary and pharmacologic interventions. Cancer Discovery. 2016;6:1315-1333.
Fernández LP, Gómez de Cedrón M, Ramírez de Molina A. Alterations of lipid metabolism in cancer: implications in prognosis and treatment. Front Oncol. 2020;10:577420.
Heuer TS, Ventura R, Mordec K, et al. FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression. EBioMedicine. 2017;16:51-62.
Falchook G, Infante J, Arkenau HT, et al. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. eClinicalMedicine. 2021;34:100797.
Tataranni T, Piccoli C. Dichloroacetate (DCA) and cancer: an overview towards clinical applications. Oxid Med Cell Longev. 2019;2019:8201079.
Kan P-C, Chang Y-J, Chien C-S, Su C-Y, Fang H-W. Coupling dichloroacetate treatment with curcumin significantly enhances anticancer potential. Anticancer Res. 2018;38:6253-6261.
Chu QSC, Sangha R, Spratlin J, et al. A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors. Invest New Drugs. 2015;33:603-610.
Brandsma D, Dorlo TPC, Haanen JH, Beijnen JH, Boogerd W. Severe encephalopathy and polyneuropathy induced by dichloroacetate. J Neurol. 2010;257:2099-2100.
Hyroššová P, Milošević M, Škoda J, Vachtenheim Jr., J, Rohlena J, Rohlenová K. Effects of metabolic cancer therapy on tumor microenvironment. Front Oncol. 2022;12:1046630.
Van Trimpont M, Peeters E, De Visser Y, et al. Novel insights on the use of l-asparaginase as an efficient and safe anti-cancer therapy. Cancers. 2022;14:902.
Ma S, Leng Y, Li X, Meng Y, Yin Z, Hang W. High spatial resolution mass spectrometry imaging for spatial metabolomics: advances, challenges, and future perspectives. TrAC Trends Anal Chem. 2023;159:116902.
He MJ, Pu W, Wang X, Zhang W, Tang D, Dai Y. Comparing DESI-MSI and MALDI-MSI mediated spatial metabolomics and their applications in cancer studies. Front Oncol. 2022;12:891018.
Carmona-Fontaine C, Bucci V, Akkari L, Deforet M, Joyce JA, Xavier JB. Emergence of spatial structure in the tumor microenvironment due to the Warburg effect. Proc Natl Acad Sci USA. 2013;110:19402-19407.
Palmer A, Phapale P, Chernyavsky I, et al. FDR-controlled metabolite annotation for high-resolution imaging mass spectrometry. Nat Methods. 2017;14:57-60.
Yoon SJ, Lee CB, Chae SU, Jo SJ, Bae SK. The comprehensive “Omics” approach from metabolomics to advanced omics for development of immune checkpoint inhibitors: potential strategies for next generation of cancer immunotherapy. Int J Mol Sci. 2021;22:6932.
Shen J, Sun N, Zens P, et al. Spatial metabolomics for evaluating response to neoadjuvant therapy in non-small cell lung cancer patients. Cancer Commun. 2022;42:517-535.
Alexandrov T. Spatial metabolomics and imaging mass spectrometry in the age of artificial intelligence. Annu Rev Biomed Data Sci. 2020;3:61-87.
Gonzalez-Covarrubias V, Martínez-Martínez E, Del Bosque-Plata L. The potential of metabolomics in biomedical applications. Metabolites. 2022;12:194.
Calligaris D, Caragacianu D, Liu X, et al. Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis. Proc Natl Acad Sci USA. 2014;111:15184-15189.
Planque M, Igelmann S, Ferreira Campos AM, Fendt SM. Spatial metabolomics principles and application to cancer research. Curr Opin Chem Biol. 2023;76:102362.
Santoro AL, Drummond RD, Silva IT, et al. In situ DESI-MSI lipidomic profiles of breast cancer molecular subtypes and precursor lesions. Cancer Res. 2020;80:1246-1257.
Ma X, Fernández FM. Advances in mass spectrometry imaging for spatial cancer metabolomics. Mass Spectrom Rev. 2022:e21804.
Zhao C, Guo L, Dong J, Cai Z. Mass spectrometry imaging-based multi-modal technique: next-generation of biochemical analysis strategy. Innovation. 2021;2:100151.
Chen X, Yi C, Yang MJ, et al. Metabolomics study reveals the potential evidence of metabolic reprogramming towards the Warburg effect in precancerous lesions. J Cancer. 2021;12:1563-1574.
Voortman J, Pham TV, Knol JC, Giaccone G, Jimenez CR. Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling. Proteome Sci. 2009;7:34.
Voillet V, Besse P, Liaubet L, San Cristobal M, González I. Handling missing rows in multi-omics data integration: multiple imputation in multiple factor analysis framework. BMC Bioinformatics. 2016;17:402.
Vahabi N, Michailidis G. Unsupervised multi-omics data integration methods: a comprehensive review. Front Genet. 2022;13:854752.
Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics data integration, interpretation, and its application. Bioinform Biol Insights. 2020;14:117793221989905.
Wörheide MA, Krumsiek J, Kastenmüller G, Arnold M. Multi-omics integration in biomedical research-a metabolomics-centric review. Anal Chim Acta. 2021;1141:144-162.
Vandereyken K, Sifrim A, Thienpont B, Voet T. Methods and applications for single-cell and spatial multi-omics. Nat Rev Genet. 2023;24:494-515.
Park J, Kim J, Lewy T, et al. Spatial omics technologies at multimodal and single cell/subcellular level. Genome Biol. 2022;23:256.
Aichler M, Walch A. MALDI imaging mass spectrometry: current frontiers and perspectives in pathology research and practice. Lab Invest. 2015;95:422-431.
Zhu X, Xu T, Peng C, Wu S. Advances in MALDI mass spectrometry imaging single cell and tissues. Front Chem. 2022;9:782432.
Grassl J, Taylor NL, Millar A. Matrix-assisted laser desorption/ionisation mass spectrometry imaging and its development for plant protein imaging. Plant Methods. 2011;7:21.
Wang J, Kunzke T, Prade VM, et al. Spatial metabolomics identifies distinct tumor-specific subtypes in gastric cancer patients. Clin Cancer Res. 2022;28:2865-2877.
Wang G, Heijs B, Kostidis S, et al. Analyzing cell-type-specific dynamics of metabolism in kidney repair. Nat Metab. 2022;4:1109-1118.
Piehowski PD, Zhu Y, Bramer LM, et al. Automated mass spectrometry imaging of over 2000 proteins from tissue sections at 100-μm spatial resolution. Nat Commun. 2020;11:8.
Prade VM, Kunzke T, Feuchtinger A, et al. De novo discovery of metabolic heterogeneity with immunophenotype-guided imaging mass spectrometry. Mol Metab. 2020;36:100953.
O'Neill KC, Dueñas ME, Larson E, Forsman TT, Lee YJ. Enhancing metabolite coverage for matrix-assisted laser desorption/ionization mass spectrometry imaging through multiple on-tissue chemical derivatizations. Methods Mol Biol. 2022;2437:197-213.
Wang G, Heijs B, Kostidis S, et al. Spatial dynamic metabolomics identifies metabolic cell fate trajectories in human kidney differentiation. Cell Stem Cell. 2022;29:1580-1593.
Tuck M, Grélard F, Blanc L, Desbenoit N. MALDI-MSI towards multimodal imaging: challenges and perspectives. Front Chem. 2022;10:904688.
Kreutzer L, Weber P, Heider T, et al. Simultaneous metabolite MALDI-MSI, whole exome and transcriptome analysis from formalin-fixed paraffin-embedded tissue sections. Lab Invest. 2022;102:1400-1405.
Dannhorn A, Swales JG, Hamm G, et al. Evaluation of formalin-fixed and FFPE tissues for spatially resolved metabolomics and drug distribution studies. Pharmaceuticals. 2022;15:1307.
Grgic A, Krestensen KK, Heeren RMA. Optimized protocol for MALDI MSI of N-glycans using an on-tissue digestion in fresh frozen tissue sections. Sci Rep. 2023;13:2776.
Bednarczyk K, Gawin M, Chekan M, et al. Discrimination of normal oral mucosa from oral cancer by mass spectrometry imaging of proteins and lipids. J Mol Histol. 2019;50:1-10.
Uchiyama Y, Hayasaka T, Masaki N, et al. Imaging mass spectrometry distinguished the cancer and stromal regions of oral squamous cell carcinoma by visualizing phosphatidylcholine (16:0/16:1) and phosphatidylcholine (18:1/20:4). Anal Bioanal Chem. 2014;406:1307-1316.
Guenther S, Muirhead LJ, Speller AVM, et al. Spatially resolved metabolic phenotyping of breast cancer by desorption electrospray ionization mass spectrometry. Cancer Res. 2015;75:1828-1837.
Yin R, Burnum-Johnson KE, Sun X, Dey SK, Laskin J. High spatial resolution imaging of biological tissues using nanospray desorption electrospray ionization mass spectrometry. Nat Protoc. 2019;14:3445-3470.
Tamura K, Horikawa M, Sato S, Miyake H, Setou M. Discovery of lipid biomarkers correlated with disease progression in clear cell renal cell carcinoma using desorption electrospray ionization imaging mass spectrometry. Oncotarget. 2019;10:1688-1703.
Towers MW, Karancsi T, Jones EA, Pringle SD, Claude E. Optimised desorption electrospray ionisation mass spectrometry imaging (DESI-MSI) for the analysis of proteins/peptides directly from tissue sections on a travelling wave ion mobility Q-ToF. J Am Soc Mass Spectrom. 2018;29:2456-2466.
Alexandrov T. Spatial metabolomics: from a niche field towards a driver of innovation. Nat Metab. 2023;5:1443-1445.